Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
Top-Rated Stocks  
NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$16.79
-0.15 (-0.89%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.69
▼
$16.97
50-Day Range
$14.96
▼
$17.12
52-Week Range
$14.87
▼
$23.40
Volume
1.76 million shs
Average Volume
2.37 million shs
Market Capitalization
$5.42 billion
P/E Ratio
17.67
Dividend Yield
N/A
Price Target
$27.70

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
65.0% Upside
$27.70 Price Target
Short Interest
Bearish
3.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.93mentions of Exelixis in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$717,600 Sold Last Quarter
Proj. Earnings Growth
103.77%
From $0.53 to $1.08 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.06 out of 5 stars

Medical Sector

9th out of 1,040 stocks

Biological Products, Except Diagnostic Industry

1st out of 175 stocks

See Top Rated MarketRank™ Stocks Here
EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

November 12, 2022 | finance.yahoo.com
Exelixis, Inc. (NASDAQ:EXEL) is a favorite amongst institutional investors who own 82%
November 12, 2022 | finance.yahoo.com
2 No-Brainer Stocks to Buy Right Now for Less than $20
November 28, 2022 | Legacy Research (Affiliate) (Ad)
See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
November 11, 2022 | bizjournals.com
Exelixis signs another big lease in Alameda
November 11, 2022 | finance.yahoo.com
Most Admired CEOs: Michael Morrissey of Exelixis
November 10, 2022 | finance.yahoo.com
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 9, 2022 | finance.yahoo.com
Here's Why This Growth Stock Is Already My 2022 Winner
November 9, 2022 | finance.yahoo.com
These 2 Value Stocks Are Cheaper Than They Appear
November 28, 2022 | Legacy Research (Affiliate) (Ad)
THE BEST BLACK FRIDAY DEAL YET
This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.
November 7, 2022 | seekingalpha.com
Exelixis: Undervalued And Unloved
November 2, 2022 | finance.yahoo.com
East Bay biotech Exelixis puts fat wallet to work with 2 deals
November 2, 2022 | finance.yahoo.com
Exelixis Inks Two Licensing Pacts For Cancer Programs
November 2, 2022 | finance.yahoo.com
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
November 2, 2022 | finance.yahoo.com
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
November 1, 2022 | finance.yahoo.com
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 1, 2022 | finance.yahoo.com
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
November 1, 2022 | finance.yahoo.com
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
November 1, 2022 | finance.yahoo.com
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
October 27, 2022 | finance.yahoo.com
Are Investors Undervaluing Exelixis (EXEL) Right Now?
October 27, 2022 | finance.yahoo.com
EXEL or TECH: Which Is the Better Value Stock Right Now?
October 26, 2022 | finance.yahoo.com
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
October 25, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 74% Upside in Exelixis (EXEL): Here's What You Should Know
October 25, 2022 | finance.yahoo.com
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
October 20, 2022 | finance.yahoo.com
Exelixis, Inc.'s (NASDAQ:EXEL) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
October 19, 2022 | nasdaq.com
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution - Nasdaq
October 19, 2022 | fool.com
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution - The Motley Fool
October 18, 2022 | seekingalpha.com
Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise - Seeking Alpha
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
11/02/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
CIK
939767
Web
www.exelixis.com
Phone
(650) 837-7000
Fax
650-837-8300
Employees
954
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$27.70
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+65.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.95
Trailing P/E Ratio
17.67
Forward P/E Ratio
31.68
P/E Growth
0.9
Net Income
$231.06 million
Net Margins
18.78%
Pretax Margin
23.43%
Return on Equity
13.11%
Return on Assets
11.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.10
Quick Ratio
6.01

Sales & Book Value

Annual Sales
$1.43 billion
Price / Sales
3.77
Cash Flow
$0.77 per share
Price / Cash Flow
21.90
Book Value
$6.99 per share
Price / Book
2.40

Miscellaneous

Outstanding Shares
322,561,000
Free Float
313,207,000
Market Cap
$5.42 billion
Optionable
Optionable
Beta
0.70

Social Links


Key Executives

  • Dr. Stelios Papadopoulos Ph.D.Dr. Stelios Papadopoulos Ph.D. (Age 74)
    Co-Founder & Independent Chair of the Board
    Comp: $98k
  • Dr. Michael M. Morrissey Ph.D. (Age 61)
    CEO, Pres & Director
    Comp: $2.37M
  • Mr. Christopher J. SennerMr. Christopher J. Senner (Age 54)
    Exec. VP & CFO
    Comp: $1.09M
  • Dr. Peter Lamb Ph.D. (Age 61)
    Exec. VP of Scientific Strategy & Chief Scientific Officer
    Comp: $909.46k
  • Mr. Jeffrey J. Hessekiel J.D.Mr. Jeffrey J. Hessekiel J.D. (Age 53)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $957.2k
  • Mr. Patrick J. Haley M.B.A.Mr. Patrick J. Haley M.B.A. (Age 46)
    MBA, Exec. VP of Commercial
    Comp: $846.43k
  • Dr. Dana T. Aftab Ph.D.
    Exec. VP of Bus. Operations
  • Ms. Susan T. Hubbard
    Exec. VP of Public Affairs & Investor Relations
  • Mr. Gregg Bernier
    VP of Marketing
  • Ms. Laura Dillard
    Exec. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

8 brokers have issued 1 year target prices for Exelixis' shares. Their EXEL share price forecasts range from $21.00 to $42.00. On average, they predict the company's stock price to reach $27.70 in the next year. This suggests a possible upside of 64.8% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2022?

Exelixis' stock was trading at $18.28 at the start of the year. Since then, EXEL stock has decreased by 8.0% and is now trading at $16.81.
View the best growth stocks for 2022 here.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 10,370,000 shares, an increase of 9.2% from the October 31st total of 9,500,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is presently 4.5 days.
View Exelixis' Short Interest.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our EXEL earnings forecast.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.19 by $0.07. The biotechnology company earned $328.42 million during the quarter, compared to analyst estimates of $366.34 million. Exelixis had a trailing twelve-month return on equity of 13.11% and a net margin of 18.78%. During the same quarter last year, the company earned ($0.10) EPS.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.57 billion-$1.60 billion, compared to the consensus revenue estimate of $1.60 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.51%), Vanguard Group Inc. (9.70%), Renaissance Technologies LLC (4.97%), State Street Corp (4.04%), Farallon Capital Management LLC (3.31%) and Price T Rowe Associates Inc. MD (2.49%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $16.81.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $5.42 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.95 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 954 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 11/28/2022 by MarketBeat.com Staff